Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 21, 2008

Gamida Obtains Rights to Amgen Cytokines to Produce Stem Cell Cancer Drug

  • Gamida Cell will use a number of cytokines from Amgen to manufacture StemEx for its pivotal registration study and subsequent commercialization. The product is being developed for hematological malignancies by Gamida Cell in a joint venture with Teva Pharmaceutical.

    Under the terms of the nonexclusive license agreement, Amgen will receive a minority equity interest in Gamida Cell in addition to royalties from sales related to hematological indications.

    StemEx is composed of ex vivo expanded cord blood stem/progenitor cells that are transplanted with nonexpanded cells from the same unit. In November 2007, the first patient enrolled in the international, multicenter trial, underwent a StemEx transplant.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »